Skip to main content
SpringerLink
Log in

Identifying and Treating Ocular Manifestations in Psoriasis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Psoriasis is a chronic immune-mediated inflammatory skin condition that commonly presents with red, thickened, and scaling plaques. Given the prominent cutaneous manifestations of psoriasis, more subtle ophthalmic findings of the disease may initially go undetected, with the potential for significant ocular morbidity. Associated ocular disease can involve nearly any structure of the eye, with the eyelids most commonly being affected, resulting in relatively common signs and symptoms of ocular surface discomfort. The presence of intraocular inflammation (i.e., uveitis) or retinal involvement carry a heightened risk of vision loss, and are often more difficult to diagnose outside of the ophthalmology clinic. Early detection and treatment of ocular disease can limit morbidity and are critical to the management of these patients, which requires coordination of care between dermatologists and ophthalmologists. The objective of this article was to review the most common ocular conditions that affect psoriatic patients, when to consider referral to an ophthalmologist, and to summarize the adverse ocular effects of current psoriasis treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reprinted with permission from Rehal et al. [12]

Fig. 2

Courtesy of Caroline Yu, MD

Fig. 3

Reprinted with permission from Rehal et al. [12]

Similar content being viewed by others

References

  1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.

    CAS  PubMed  Google Scholar 

  2. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.

    PubMed  Google Scholar 

  3. Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133(2):287–9.

    CAS  PubMed  Google Scholar 

  4. Parisi R, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.

    CAS  PubMed  Google Scholar 

  5. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.

    CAS  PubMed  Google Scholar 

  6. Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023–9.

    PubMed  Google Scholar 

  7. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.

    CAS  PubMed  Google Scholar 

  8. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.

    CAS  PubMed  Google Scholar 

  9. Chandran NS, et al. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis. J Dermatol. 2007;34(12):805–10.

    PubMed  Google Scholar 

  10. Cruz N, et al. Ocular manifestations of psoriasis. Arq Bras Oftalmol. 2018;81(3):219–25.

    PubMed  Google Scholar 

  11. Abbagani S, Kamath YS, Nayak S. A study on ocular morbidity among patients with psoriasis visiting a Tertiary Care Hospital in Karnataka, Southern India. Ocul Immunol Inflamm. 2019;27(4):531–4.

    PubMed  Google Scholar 

  12. Rehal B, et al. Ocular psoriasis. J Am Acad Dermatol. 2011;65(6):1202–12.

    PubMed  Google Scholar 

  13. Webster GF, Durrani K, Suchecki J. Ocular rosacea, psoriasis, and lichen planus. Clin Dermatol. 2016;34(2):146–50.

    PubMed  Google Scholar 

  14. Gonzalez-Andrades M, et al. Sterile corneal infiltrates secondary to psoriasis exacerbations: topical tacrolimus as an alternative treatment option. Eye Contact Lens. 2017;43(1):e1–3.

    PubMed  Google Scholar 

  15. Donshik PC, Hoss DM, Ehlers WH. Inflammatory and papulosquamous disorders of the skin and eye. Dermatol Clin. 1992;10(3):533–47.

    CAS  PubMed  Google Scholar 

  16. Eustace P, Pierse D. Ocular psoriasis. Br J Ophthalmol. 1970;54(12):810–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Bernhard JD. Is eyelid involvement a sign of severe psoriasis? Dermatologica. 1987;174(3):151.

    CAS  PubMed  Google Scholar 

  18. Ajitsaria R, et al. Psoriasis, psoriatic arthropathy and relapsing orbital myositis. Clin Exp Dermatol. 2001;26(3):274–5.

    CAS  PubMed  Google Scholar 

  19. Ssi-Yan-Kai I, Pearson A. Orbital myositis and psoriatic arthritis. Can J Ophthalmol. 2012;47(6):e42–3.

    PubMed  Google Scholar 

  20. Kilic B, et al. Ocular findings in patients with psoriasis. Int J Dermatol. 2013;52(5):554–9.

    PubMed  Google Scholar 

  21. Zengin N, et al. Tear film and meibomian gland functions in psoriasis. Acta Ophthalmol Scand. 1996;74(4):358–60.

    CAS  PubMed  Google Scholar 

  22. Her Y, Lim JW, Han SH. Dry eye and tear film functions in patients with psoriasis. Jpn J Ophthalmol. 2013;57(4):341–6.

    PubMed  Google Scholar 

  23. Aragona E, et al. Tear film and ocular surface assessment in psoriasis. Br J Ophthalmol. 2018;102(3):302–8.

    PubMed  Google Scholar 

  24. Karabulut AA, et al. Conjunctival impression cytology and tear-film changes in patients with psoriasis. Cornea. 1999;18(5):544–8.

    CAS  PubMed  Google Scholar 

  25. Demirci G, et al. Tear osmolarity and ocular surface parameters in patients with psoriasis. Arq Bras Oftalmol. 2017;80(1):1–3.

    PubMed  Google Scholar 

  26. Huynh N, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008;16(3):89–93.

    CAS  PubMed  Google Scholar 

  27. Amin KA, Belsito DV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis. 2006;55(5):280–5.

    PubMed  Google Scholar 

  28. Demerdjieva Z, Mazhdrakova I, Tsankov N. Ocular changes in patients with psoriasis. Clin Dermatol. 2019;37(6):663–7.

    PubMed  Google Scholar 

  29. Catsarou-Catsari A, et al. Ophthalmological manifestations in patients with psoriasis. Acta Derm Venereol. 1984;64(6):557–9.

    CAS  PubMed  Google Scholar 

  30. Vrabec F. Histologic description of a case of psoriasis with conjunctival, corneal and cutaneous localization. Ophthalmologica. 1952;124(2):105–8 (In undetermined language).

    CAS  PubMed  Google Scholar 

  31. Amer R, Levinger N. Psoriasis-associated progressive necrotizing posterior scleritis: a 6-year follow-up. Eur J Ophthalmol. 2020;30(3):Np7–10.

    PubMed  Google Scholar 

  32. Stacy RC, et al. Posterior necrotizing scleritis presenting as sectoral chorioretinitis. Ocul Immunol Inflamm. 2015;23(5):412–5.

    PubMed  Google Scholar 

  33. Altan-Yaycioglu R, et al. Posterior scleritis in psoriatic arthritis. Retina. 2003;23(5):717–9.

    PubMed  Google Scholar 

  34. Boss JM, et al. Peripheral corneal melting syndrome in association with psoriasis: a report of two cases. Br Med J (Clin Res Ed). 1981;282(6264):609–10.

    CAS  Google Scholar 

  35. Moadel K, et al. Psoriatic corneal abscess. Am J Ophthalmol. 1995;119(6):800–1.

    CAS  PubMed  Google Scholar 

  36. Herbert VG, et al. Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease. Br J Dermatol. 2014;170(3):746–8.

    CAS  PubMed  Google Scholar 

  37. Filev FS, et al. Psoriasis-associated keratitis: case report. Ophthalmologe. 2014;111(12):1201–3 (In German).

    CAS  PubMed  Google Scholar 

  38. Jeng BH, Downs-Kelly E, Langston RH. Superficial hypertrophic dendritic epitheliopathy occurring before and after penetrating keratoplasty in a patient with psoriasis. Cornea. 2006;25(9):1097–9.

    PubMed  Google Scholar 

  39. Lafond G, Roy PE, Grenier R. Lens opacities appearing during therapy with methoxsalen and long-wavelength ultraviolet radiation. Can J Ophthalmol. 1984;19(4):173–5.

    CAS  PubMed  Google Scholar 

  40. See JA, Weller P. Ocular complications of PUVA therapy. Australas J Dermatol. 1993;34(1):1–4.

    CAS  PubMed  Google Scholar 

  41. DePry J, et al. Phototherapy-related ophthalmologic disorders. Clin Dermatol. 2015;33(2):247–55.

    PubMed  Google Scholar 

  42. Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231–7.

    PubMed  Google Scholar 

  43. Woo TY, et al. Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient. Arch Dermatol. 1985;121(10):1307–8.

    CAS  PubMed  Google Scholar 

  44. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16.

    PubMed  Google Scholar 

  45. Fraga NA, et al. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87(6):877–83.

    PubMed  PubMed Central  Google Scholar 

  46. Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol. 2005;139(1):106–11.

    PubMed  Google Scholar 

  47. Knox DL. Psoriasis and intraocular inflammation. Trans Am Ophthalmol Soc. 1979;77:210–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35(4):354–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Chi CC, et al. Risk of uveitis among people with psoriasis: a Nationwide Cohort Study. JAMA Ophthalmol. 2017;135(5):415–22.

    PubMed  PubMed Central  Google Scholar 

  50. Abbouda A, et al. Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin Ophthalmol. 2017;32(6):715–20.

    PubMed  Google Scholar 

  51. Lam M, et al. The incidence and prevalence of uveitis in psoriasis: a systematic review and meta-analysis. J Cutan Med Surg. 2020;24(6):601–7.

    PubMed  Google Scholar 

  52. Egeberg A, et al. Association of psoriatic disease with uveitis: a Danish Nationwide Cohort Study. JAMA Dermatol. 2015;151(11):1200–5.

    PubMed  Google Scholar 

  53. Okamoto F, et al. Factors associated with increased aqueous flare in psoriasis. Jpn J Ophthalmol. 2001;45(2):172–6.

    CAS  PubMed  Google Scholar 

  54. Oon HH, et al. Acute unilateral red eye in a patient with psoriasis. Clin Exp Dermatol. 2019;44(8):924–6.

    CAS  PubMed  Google Scholar 

  55. Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks. Psoriasis (Auckl). 2019;9:91–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Abu-Yaghi NE, et al. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm. 2011;19(6):426–30.

    PubMed  PubMed Central  Google Scholar 

  57. Hesse S, et al. Psoriasis and birdshot chorioretinopathy: response to aromatic retinoids. Dermatology. 1993;187(2):137–9.

    CAS  PubMed  Google Scholar 

  58. Weinstein JE, Pepple KL. Cytokines in uveitis. Curr Opin Ophthalmol. 2018;29(3):267–74.

    PubMed  PubMed Central  Google Scholar 

  59. Dai YX, et al. Risk of retinal diseases in patients with psoriasis: a population-based cohort study in Taiwan. J Dermatol. 2021;48(10):1550–6.

    PubMed  Google Scholar 

  60. Castellino N, et al. Retinal vascular assessment in psoriasis: a multicenter study. Front Neurosci. 2021;15:30.

    Google Scholar 

  61. Enos CW, et al. Peripheral retinal vascular leakage in moderate to severe psoriasis: a pilot study. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.05.067 (Epub 28 May 2019).

    Article  PubMed  Google Scholar 

  62. Aksoy M, Toptan M, An I. Retinal nerve fiber layer thickness and choroidal thickness: an evaluation in psoriasis patients. Int J Clin Pract. 2021;75(4): e13904.

    CAS  PubMed  Google Scholar 

  63. Ersan I, et al. Evaluation of macular ganglion cell-inner plexiform layer and choroid in psoriasis patients using enhanced depth imaging spectral domain optical coherence tomography. Ocul Immunol Inflamm. 2017;25(4):520–4.

    PubMed  Google Scholar 

  64. Kılıç R, et al. Choroidal thickness in psoriasis. Int Ophthalmol. 2017;37(1):173–7.

    PubMed  Google Scholar 

  65. Kao LT, et al. Association between psoriasis and neovascular age-related macular degeneration: a population-based study. J Am Acad Dermatol. 2015;72(6):1090–2.

    PubMed  Google Scholar 

  66. Yen YC, et al. Risk of retinal vein occlusion in patients with psoriasis: a population-based cohort study. Retina. 2015;35(9):1786–94.

    PubMed  Google Scholar 

  67. Ghalamkarpour F, et al. Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatolog Treat. 2020;31(1):27–32.

    CAS  PubMed  Google Scholar 

  68. Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020;10(1):11.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Cram DL. Corneal melting in psoriasis. J Am Acad Dermatol. 1981;5(5):617.

    CAS  PubMed  Google Scholar 

  70. Fraunfelder FT, Fraunfelder FW. Possible association between apremilast therapy and increased tearing. Ophthalmic Plast Reconstr Surg. 2021;37(3 Suppl):S31–2.

    PubMed  Google Scholar 

  71. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275–9.

    CAS  PubMed  Google Scholar 

  72. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299–305.

    CAS  PubMed  Google Scholar 

  73. Lebowitz MA, Berson DS. Ocular effects of oral retinoids. J Am Acad Dermatol. 1988;19(1 Pt 2):209–11.

    CAS  PubMed  Google Scholar 

  74. Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol. 2004;122(6):928–30.

    PubMed  Google Scholar 

  75. LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181–8.

    CAS  PubMed  Google Scholar 

  76. Cunningham ET Jr, et al. Drug-induced inflammation in patients on TNFα inhibitors. Ocul Immunol Inflamm. 2012;20(1):2–5.

    CAS  PubMed  Google Scholar 

  77. Damento G, et al. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2014;89(11):1481–6.

    CAS  PubMed  Google Scholar 

  78. Drury J, Hickman SJ. Internuclear ophthalmoplegia associated with anti-TNFα medication. Strabismus. 2015;23(1):30–2.

    PubMed  Google Scholar 

  79. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35(8):751–6.

    CAS  PubMed  Google Scholar 

  80. Leal I, et al. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis—a systematic review. Acta Ophthalmol. 2018;96(6):e665–75.

    PubMed  Google Scholar 

  81. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A Registry-Based Study. Arthritis Rheum. 2007;56(10):3248–52.

    CAS  PubMed  Google Scholar 

  82. Montero JA, et al. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol. 2006;16(2):343–5.

    CAS  PubMed  Google Scholar 

  83. Seror R, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868–74.

    CAS  Google Scholar 

  84. Tsilimbaris M, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009;247(8):1119–25.

    CAS  PubMed  Google Scholar 

  85. Wendling D, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–21.

    CAS  PubMed  Google Scholar 

  86. Wendling D, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503–10.

    PubMed  Google Scholar 

  87. Winthrop KL, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155(1):183-189.e1.

    PubMed  Google Scholar 

  88. Arriola-Villalobos P, et al. Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye (Lond). 2008;22(4):599–600.

    CAS  Google Scholar 

  89. Brito-Zerón P, Perez-Alvarez R, Ramos-Casals M. Etanercept and uveitis: friends or foes? Curr Med Res Opin. 2015;31(2):251–2.

    PubMed  Google Scholar 

  90. Gaujoux-Viala C, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233–9.

    CAS  PubMed  Google Scholar 

  91. Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom. 2020;103(2):148–54.

    PubMed  Google Scholar 

  92. Lezcano Carduz VP, Mingo Botín D, Durán Poveda SP. Squamous cell neoplasm of the ocular surface in a patient with psoriasis treated with tumor necrosis factor-alpha inhibitors. Cornea. 2015;34(7):833–4.

    PubMed  Google Scholar 

  93. Matet A, et al. Systemic adalimumab induces peripheral corneal infiltrates: a case report. BMC Ophthalmol. 2015;15:57.

    PubMed  PubMed Central  Google Scholar 

  94. Noguera-Pons R, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005;39(12):2131–5.

    PubMed  Google Scholar 

  95. Taban M, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14(3):145–50.

    PubMed  Google Scholar 

  96. Tauber T, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006;10(1):26–9.

    PubMed  Google Scholar 

  97. Yokoyama W, Takada K, Miyasaka N, Kohsaka H. Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep. 2014 Aug 1; 2014:bcr-2014-205779.

  98. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004;122(5):793–4.

    PubMed  Google Scholar 

  99. Teo HMT, de Sá FF, Demirci H. Association of blepharitis and ectropion with tumor necrosis factor α inhibitor treatment in crohn disease. JAMA Ophthalmol. 2019;137(2):232–3.

    PubMed  Google Scholar 

  100. Yoshida M, et al. Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy. Int Ophthalmol. 2018;38(2):841–7.

    PubMed  Google Scholar 

  101. Manzano RP, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2008;246(6):907–11.

    CAS  PubMed  Google Scholar 

  102. Becerra CMC, et al. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol. 2020;5(1): e000331.

    Google Scholar 

  103. Song WK, Cho AR, Yoon YH. Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report. BMC Ophthalmol. 2018;18(1):156.

    PubMed  PubMed Central  Google Scholar 

  104. Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–3.

    CAS  PubMed  Google Scholar 

  105. Martinez CE, Allen JB, Davidorf FH, Cebulla CM. Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. BMJ Case Rep. 2017 Jun 29; 2017:bcr2017219296.

  106. Javadzadeh S, et al. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. Clin Exp Dermatol. 2020;45(6):802–4.

    CAS  PubMed  Google Scholar 

  107. Ruggiero A, et al. Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.

    PubMed  PubMed Central  Google Scholar 

  108. Grzybowski A, et al. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93(5):402–10.

    PubMed  Google Scholar 

  109. Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect. 2012;2(3):145–7.

    PubMed  PubMed Central  Google Scholar 

  110. Saffra N, Astafurov K. Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol. 2017;9(1):60–4.

    PubMed  PubMed Central  Google Scholar 

  111. Schechet SA, et al. Acute retinal necrosis after administration of adalimumab, a systemic antitumor necrosis factor antibody. Retin Cases Brief Rep. 2018;12(4):307–9.

    PubMed  Google Scholar 

  112. Dermawan A, et al. Infliximab-induced optic neuritis. BMJ Case Rep. 2020;13(12): e236041.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, The University of Iowa, Iowa City, IA, USA

    Mahsaw Motlagh & Christopher Fortenbach

  2. Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA

    Howard I. Maibach

  3. Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, CA, USA

    Bobeck S. Modjtahedi

  4. Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA

    Bobeck S. Modjtahedi

  5. Eye Monitoring Center, Kaiser Permanente Southern California, 1011 Baldwin Park Boulevard, Balwin Park, CA, 91706, USA

    Bobeck S. Modjtahedi

Authors
  1. Mahsaw Motlagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher Fortenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard I. Maibach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bobeck S. Modjtahedi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bobeck S. Modjtahedi.

Ethics declarations

Funding

No funding was received for this study.

Conflicts of Interest

Mahsaw Motlagh, Christopher Fortenbach, and Howard I. Maibach have no conflicts of interest to declare. Bobeck S. Modjtahedi has received research support from Genentech outside the submitted work.

Ethics Approval

Not required for this review.

Consent to Participate

Not applicable.

Consent for Publication

Figures 1 and 3 were reprinted from Rehal et al. [12], with permission.

Availability of Data and Material (Data Transparency)

Not applicable.

Author Contributions

MM literature search, analysis, and manuscript draft; CF literature search, analysis, and manuscript draft; HIM manuscript draft and critical revisions; BSM study conception, manuscript draft, and critical revisions. All authors reviewed and approved the final version of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Motlagh, M., Fortenbach, C., Maibach, H.I. et al. Identifying and Treating Ocular Manifestations in Psoriasis. Am J Clin Dermatol 23, 51–60 (2022). https://doi.org/10.1007/s40257-021-00648-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-021-00648-x

Search

Navigation